Various ethnic groups differ in what specific symptoms of systemic lupus erythematosus (SLE) they display — a difference that might be linked to the presence of different immune factors, according to a new study. Understanding how ethnicity might influence these differences can pave the way for treatments that are better…
Treatment of systemic lupus erythematosus (SLE) needs to reflect the involvement of particular organs as well as the severity of disease, according to a study presented at the Congress of Clinical Rheumatology Annual Meeting, scrutinizing published clinical trials of lupus. The study advocated giving more weight to clinical experience…
The Alliance for Lupus Research (ALR) partnered with Willie Colon, the former New York Jets offensive guard, for the second Annual Willie Colon Charity Golf Outing fundraiser benefitting the ALR Jean Davis Research Grant. Money raised at the event is used to further ALR-targeted research efforts. Other former National Football League players who attended…
Bridget Hood, a Lupus L.A. board member who lives with the disease, has published an editorial in a California newspaper to mark May — Lupus Awareness Month — and to raise awareness of lupus and advocate for new research into potential treatments or a cure. Specifically, Hood called on policymakers to do…
The Defense Appropriations Committee of the U.S. House of Representatives passed a bill allocating $5 million in new funding for a peer-reviewed Lupus Medical Research Program on May 17. The program, included in a 2017 Defense Appropriations spending bill, is to be operated by the U.S. Defense Department. A…
Researchers have identified an enzyme called SHP-2 whose levels are significantly increased in blood samples of lupus patients and in systemic lupus erythematosus (SLE) mouse models, which can become a potential therapeutic target for patients suffering from this disease. The study, “Inhibition of SHP2 ameliorates the pathogenesis of systemic lupus…
Today — Wednesday, May 18 — the six Lupus Agencies of New York State will be guests in the New York State Senate and Assembly as both houses recognize May as the 8th annual Lupus Awareness Month in the state. Legislative sponsors of the event are State Sen. Joseph Griffo…
The U.S. National Institute of Allergy and Infectious Disease (NIAID) has awarded $225,000 to Karyopharm Therapeutics to advance the development of its SINE nuclear transport compound, KPT-350, to treat neurological, inflammatory and autoimmune diseases. The grant will be used in preclinical trials of the compound as a treatment for systemic lupus erythematosus (SLE), which will…
Disrupted neuroimmune signaling contributes to cognitive problems in neuropsychiatric systemic lupus erythematosus (SLE), according to a study presented at the Congress of Clinical Rheumatology 2016 Annual Meeting, reported by Healio Rheumatology. These new insights into the molecular mechanisms of lupus might provide targets for the development of therapies for…
Findings from a large “Treat-to-Target” (T2T) study of systemic lupus erythematosus (SLE), focusing on patient and disease characteristics, and factors influencing a low disease activity state — associated with better long-term outcomes — were presented at the recent Australian Rheumatology Association Annual Scientific Meeting in Darwin. Treat-to-Target (T2T), an approach used for the design…